Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
2024年7月15日 - 2:30PM
RNSを含む英国規制内ニュース (英語)
Crossject to attend H.C. Wainwright 26th Annual Global Investment
Conference
Dijon, France, July
15th 2024, 07:30 CET
-- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty
pharma company in advanced phases of development and registration
for ZEPIZURE®, its emergency treatment
for the management of epileptic crises based on its award-winning
needle-free auto-injector ZENEO®, announces it will attend the H.C.
Wainwright 26th Annual Global Investment Conference, taking place
in New York September 9-11, 2024.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma company
based in France and the U.S. It is in advanced regulatory
development for ZEPIZURE®, an
epileptic rescue therapy, for which it was awarded a $60 million
contract with the U.S.
Biomedical Advanced Research and Development Authority (BARDA).
ZEPIZURE® is based on the Company’s award-winning needle-free
autoinjector ZENEO®, designed to enable patients and untrained
caregivers to easily and instantly deliver emergency medication via
intramuscular
injection on bare skin or even through clothing. The Company’s
other products in development
include rescue therapies for allergic shocks, adrenal
insufficiencies, opioid overdose and asthma
attacks.
For further information, please contact:
Investors
Natasha Drapeau
Cohesion Bureau
+41 76 823 75 27
natasha.drapeau@cohesionbureau.com
|
Media
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49
sophie.baumont@cohesionbureau.com |
|
Crossject (EU:ALCJ)
過去 株価チャート
から 6 2024 まで 7 2024
Crossject (EU:ALCJ)
過去 株価チャート
から 7 2023 まで 7 2024